ACADIA Pharmaceuticals Inc (ACAD) Q3 2025 Earnings Call Highlights: Record Sales and Strategic ... [Yahoo! Finance]
ACADIA Pharmaceuticals Inc. (ACAD)
Last acadia pharmaceuticals inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-irhome
Company Research
Source: Yahoo! Finance
DAYBUE Net Sales: $101.1 million, marking the highest revenue and prescription volume since launch. NUPLAZID Net Sales: $177.5 million, representing a 12% year-over-year growth. Gross-to-Net Adjustment for DAYBUE: Gross-to-Net Adjustment for NUPLAZID: R&D Expenses: $87.8 million, up from $66.6 million in the previous year. SG&A Expenses: $133.4 million, flat compared to the prior year. Cash Balance: $847 million at the end of the quarter. Full-Year 2025 Guidance for NUPLAZID: Raised to $685 million to $695 million. Full-Year 2025 Guidance for DAYBUE: Adjusted to $385 million to $400 million. Full-Year 2025 R&D Expense Guidance: $335 million to $345 million. Full-Year 2025 SG&A Expense Guidance: $540 million to $555 million. Warning! GuruFocus has detected 3 Warning Sign with ACAD. Is ACAD fairly valued? Test your thesis with our free DCF calculator. Release Date: November 05, 2025 For the complete transcript of the earnings call, please refer to the full e
Show less
Read more
Impact Snapshot
Event Time:
ACAD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACAD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACAD alerts
High impacting ACADIA Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
ACAD
News
- Buy Acadia Pharmaceuticals For Daybue/Nuplazid Stability And Pipeline Optionality [Seeking Alpha]Seeking Alpha
- ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- Acadia to pivot to Alzheimer's psychosis pipeline, accd to Wall Street analysts [Yahoo! Finance]Yahoo! Finance
- ACADIA Pharmaceuticals (NASDAQ:ACAD) was given a new $29.00 price target on by analysts at Mizuho.MarketBeat
- Acadia Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference [Yahoo! Finance]Yahoo! Finance
ACAD
Earnings
- 11/5/25 - Beat
ACAD
Sec Filings
- 11/19/25 - Form 4
- 11/19/25 - Form 4
- 11/14/25 - Form SCHEDULE
- ACAD's page on the SEC website